West Pharmaceutical Services, Inc. (WST)
Estimates & Forecasts•Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
West Pharmaceutical Services, Inc. (WST)Proprietary model projects FY+1 EPS of $8.25 with +4.8% revenue growth at 55/100 confidence. Inline consensus estimate using the industrial / operating company framework.
USD · WST · Proprietary Model| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $3.1B | $3.4B | $3.5B | $3.7B | $3.9B |
| Net Income | $494M | $587M | $629M | $654M | $696M |
| EPS (Diluted) | $6.80 | $8.25 | $8.97 | $9.45 | $10.20 |
| Free Cash Flow | $469M | $478M | $501M | $527M | $556M |
| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Revenue | $3.0B | $2.9B | $3.1B | $3.4B | $3.5B | $3.7B | $3.9B |
| YoY Growth | +2.3% | -2.0% | +6.3% | +4.8% | +5.0% | +5.3% | +5.7% |
| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Operating Income | $711M | $595M | $617M | $707M | $750M | $796M | $847M |
| Operating Margin | 24.1% | 20.6% | 20.1% | 20.9% | 21.2% | 21.3% | 21.5% |
| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Net Income | $593M | $493M | $494M | $587M | $629M | $654M | $696M |
| EPS (Diluted) | $7.88 | $6.69 | $6.80 | $8.25 | $8.97 | $9.45 | $10.20 |
| YoY Growth | +1.3% | -17.0% | +0.2% | +18.8% | +7.2% | +3.9% | +6.5% |
| Net Margin | 20.1% | 17.0% | 16.1% | 17.4% | 17.7% | 17.5% | 17.7% |
Forecast is usable, but expect normal estimate drift around earnings and macro events.
Quick answers to common questions about WST estimates and forecasts.
West Pharmaceutical Services, Inc.'s projected EPS for next fiscal year is $8.25, representing a +10.1% growth YoY. This forecast has a confidence score of 55/100 and uses the industrial / operating company framework.
EarningsThe 12-month base price target is $404 (implying a +23.0% return from the current price of $328.03). Bear and bull scenario targets are $254 and $532 respectively.
ForecastRevenue is expected to grow 4.8% next fiscal year, reaching approximately $3.4 billion, blending historical trends with near-term analyst expectations.
GrowthEstimates carry a confidence score of 55/100. This indicates moderate conviction with normal expected variance around earnings releases. Reliability is evaluated based on data depth and consensus alignment.
MethodologyOperating margin is projected at 20.9% next fiscal year. Margins are currently contracting (cost pressures).
EarningsThe model blends historical SEC statements with near-term consensus analyst expectations for the first two years (FY1 and FY2), transitioning to purely data-driven, long-term mathematical projection rules for years three and four.
MethodologyRisks include macro disruptions, margin contraction, or low growth. The bear case price target of $254 represents a 37% discount to the base case, highlighting downside potential in pessimistic conditions.
RiskOur FY+1 EPS projection of $8.25 is inline consensus of $8.61 (a difference of 5.6%).
ForecastDisclaimer: This page is for informational purposes only and does not constitute financial advice. Financial forecasts and estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.